Faculty Members
Sean Barbour
PLENARY SESSION 2: IIGANN Research Group Lecture 1
Risk prediction: What is on the Horizon?
DAY 1: Thursday 18 September 2025, 11:30–11:50
I completed my internal medicine and nephrology training at the University of British Columbia (BC) in 2010. I subsequently did a three-year glomerulonephritis fellowship and Master of Science in clinical epidemiology at the University of Toronto. I am an Associate Professor with the UBC Division of Nephrology, with a clinical and research focus on glomerular diseases. I am the Medical Lead and Chair of the BC Renal Glomerulonephritis Committee and GN Registry. Through these positions, I am responsible for health policy and health services related to glomerular diseases in BC. My research focus is on clinical trials, health outcomes and health services delivery in glomerulonephritis, and using prediction modeling techniques to improve risk stratification in glomerular diseases. I am the Chair of the International IgA Nephropathy Network Research Group and hold multiple peer-reviewed grants, including from the Michael Smith Foundation for Health Research, the Kidney Foundation of Canada, and the Canadian Institutes of Health Research.
Dr. Sean Barbour completed his internal medicine and nephrology training at the University of British Columbia (BC) in 2010. He subsequently did a three-year glomerulonephritis fellowship and Master of Science in clinical epidemiology at the University of Toronto. He is an Associate Professor with the UBC Division of Nephrology, with a clinical and research focus on glomerular diseases. He is the Medical Lead and Chair of the BC Renal Glomerulonephritis Committee and GN Registry. Through these positions, he is responsible for health policy and health services related to glomerular diseases in BC. His research focus is on clinical trials, health outcomes and health services delivery in glomerulonephritis, and using prediction modeling techniques to improve risk stratification in glomerular diseases. He is the Chair of the International IgA Nephropathy Network Research Group and holds multiple peer-reviewed grants, including from the Michael Smith Foundation for Health Research, the Kidney Foundation of Canada, and the Canadian Institutes of Health Research.
Peter Boor
PLENARY SESSION 5: IIGANN Research Group Lecture 2
Pathomics and next generation pathology in IgAN and IgAVN
DAY 2: Friday 19 September 2025, 11:30–11:50
Professor Peter Boor received his medical and scientific training at the Medical Schools of Bratislava in Slovakia and Aachen Germany. He is the chair of Translational Nephropathology and senior consultant pathologist at the Institute of Pathology at the RWTH Aachen University. He also leads the Electron Microscopy Facility and Digital Pathology and is the RWTH Lecturer. He is a member of several national and international societies of pathology, renal pathology, and nephrology and received several prestigious awards and prizes for academic, clinical, and teaching excellence. His research group, the LaBooratory of Nephropathology, focuses on diagnostic biomarkers with a particular focus on imaging, digital pathology, and AI, as well as in vivo animal modeling, and understanding of pathological processes in CKD, fibrosis, and (micro)vasculature. He founded and is leading the German National Autopsy Registry (NAREG) and Research Network (NATON) and other research consortia. His scientific work encompasses more than 340 original papers, reviews and editorials, and several book chapters.
Chee Kay Cheung
PLENARY SESSION 1: IgAN Natural History
Europe
DAY 1: Thursday 18 September 2025, 10:00–11:00
Dr. Chee Kay Cheung is a Consultant Nephrologist and Honorary Associate Professor at the University Hospitals of Leicester, United Kingdom. His clinical and research interests are in glomerular diseases, including in IgA nephropathy, vasculitis and lupus nephritis. He leads a number of investigator-initiated studies in this area, and has served as UK national chief investigator and principal investigator on multiple clinical trials. He leads specialist clinics in glomerular diseases and in vasculitis and lupus nephritis. He is a steering committee member of the International IgAN Network, and active member of the UK IgAN, membranous nephropathy and lupus nephritis rare disease groups.
John Feehally
Perspectives in IgAN: Where are we and where do we need to go next?
Speaker
DAY 3: Saturday 20 September 2025, 09:00–10:00
John Feehally was a nephrologist in Leicester, and is an honorary professor of renal medicine at the University of Leicester, UK.
He was active in IgA nephropathy research for nearly forty years from the early 1980s and was involved in studies of pathogenesis, classification and treatment of IgA nephropathy. He was a co-founder of the International IgA Nephropathy Network.
Jürgen Floege
PLENARY SESSION 6: Treatment 1
What do the KDIGO Guidelines NOT tell us?
DAY 2: Friday 19 September 2025, 14:00–15:00
Professor Jürgen Floege trained at the Hannover Medical School, Germany, the Albert Einstein College of Medicine, New York and the University of Washington, Seattle, USA. He was head of the Division of Nephrology and Immunology at the University of Aachen, Germany from 1999 to July 31, 2023. Thereafter he was awarded the position of a senior professor at the RWTH Aachen University Medical School.
Professor Floege is a former executive council member of the International Society of Nephrology (ISN), the European Renal Association (ERA-EDTA), and KDIGO. He is a Distinguished Fellow of the ERA-EDTA and recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology. He also is past-president of the German Society of Nephrology and recipient of the 2020 Volhard medal of that society in honor of his life-time achievements. Together with Professors Richard Johnson and Marcello Tonelli he edits the best-selling textbook “Comprehensive Clinical Nephrology”. Finally, Professor Floege is associate editor of Kidney International since Jan 2018 and editor-in-chief of Clinical Kidney Journal since September 2023. Until 2017 he served as associate editor of Nephrology, Dialysis Transplantation.
Research interests encompass both basic research, i.e. studies underlying progression of renal disease in particular renal fibrosis, as well as clinical research in immune-mediated renal disease, in particular IgA-nephropathy, as well as bone and mineral disorders (CKD-MBD) and cardiovascular disease in uremic patients. He coordinates the KDIGO world-wide guidelines on the management of glomerular diseases.
His scientific work encompasses more than 770 original papers, reviews and editorials.
Loreto Gesualdo
Perspectives in IgAN: Where are we and where do we need to go next?
Chair
DAY 3: Saturday 20 September 2025, 09:00–10:00
Prof. Loreto Gesualdo was born in Altamura (Ba) on December 27, 1960, he graduated in Medicine and Surgery at the University of Bari with 110/100 cum laude and Specialized in Nephrology at the University of Chieti. From September 1987 to August 1990, he carried out research activities at the Case Western Reserve University of Cleveland (USA) and, after, from September 1997 to December 1998, at the University of Pittsburgh (USA).
His research activity focuses on the pathogenetic aspects of glomerulonephritides (IgAN, MN, DKD) and renal fibrosis. His scientific activity is documented in PubMed by 685 publications. He has participated in more than 300 national and international scientific meetings; he has written 18 books. Its total impact factor is greater than 2000; his works have been cited in Google Scholar 31146 times and he has an H-score of 90 which lists him among the top 100 Italian scientists. He has filed 4 patents and participated in the establishment of an innovative start-up and a spin-off.
Winner as principal investigator of several international, European, national and regional projects. Since 2010 he is Full Professor of Nephrology at the University of Bari and Director of Nephrology, Dialysis and Transplantation Unit at the Bari Polyclinic, he is currently Regional Transplant Coordinator, Apulia Region. He is also Director of the Nephrology Resident Program, School of Medicine, University of Bari and Director of the International Summer School of Renal Pathology (ISSRP) and collaborates with many colleagues from European and international countries (United States, Canada, France, Holland, Cyprus, Germany, Spain, Czech Republic, Sweden, United Kingdom, Uganda).
From 2016 to 2018, he was President of the Italian Society of Nephrology, councillor member of the European Renal Association (ERA-EDTA), he was on the Board of Directors of the Renal Pathology Society and Chairman of the Continuous Medical Education Committee of the European Society of Nephrology ERA-EDTA. From 2016 to 2021 he was Dean of the Bari School of Medicine. From 2018 to 2022, he was President of the Italian Kidney Foundation.
Currently he is President of Italian Foundation of scientific society (FISM) and he coordinates a humanitarian project for the construction of a Renal Immunopathology centre and dialysis unit with Telemedicine service in Mbarara, Uganda.
James Gleeson
PLENARY SESSION 3: IgAN Pathogenesis 1
Where does pathogenic IgA come from?
DAY 1: Thursday 18 September 2025, 14:00–15:00
Dr. James Gleeson is a Nephrologist at Hôpital Bichat – Claude-Bernard, Paris, France. He studied Medicine at the University of Galway, and completed post-graduate training in General Internal Medicine and Nephrology with the Royal College of Physicians of Ireland. He has a Masters in Immunology and his PhD investigated the gut-kidney axis in IgA nephropathy.
Mark Haas
PLENARY SESSION 5: IIGANN Research Group Lecture 2
Pathomics and next generation pathology in IgAN and IgAVN
DAY 2: Friday 19 September 2025, 11:30–11:50
Mark Haas is a renal pathologist at Cedars-Sinai Medical Center in Los Angeles, CA, USA, and Professor of Pathology, Cedars-Sinai Professorial Series. He is a past president of the Renal Pathology Society (2008) and was the recipient of its Jacob Churg Award for Outstanding Contributions in Renal Pathology in 2012 and Robert H. Heptinstall Lifetime Achievement Award in 2023. He currently serves on the editorial boards of Kidney International (since 2002), Clinical Nephrology, and Histopathology (International Editorial Advisory Board), and was an Associate Editor of the American Journal of Transplantation from 2014-2021. He also served on the Program Committee for the Banff Conferences on Allograft Pathology from 2011–2019, chairing this Committee for the 2013 and 2017 conferences. His main interests are glomerular diseases, especially IgA nephropathy, and kidney transplant pathology.
Bruce A. Julian
PLENARY SESSION 1: IgAN Natural History
Chair
DAY 1: Thursday 18 September 2025, 10:00–11:00
Dr. Bruce A. Julian is Professor Emeritus, Volunteer Faculty, at the University of Alabama at Birmingham (UAB) School of Medicine in Birmingham, Alabama, USA. His interest in the pathogenesis and clinical expression of IgAN started in 1978 during his nephrology fellowship at the University of Kentucky. Discovery of a multiplex family with IgAN in private practice prompted a move to UAB in 1984 to begin a career as a clinician scientist. Collaborative studies with the UAB team and national and international investigators led to a more detailed understanding of the complex genetic influences on IgAN and a four-hit hypothesis for an autoimmune disease mechanism that serves as a blue-print for testing approaches for disease-targeted therapy. During his service as a transplant nephrologist at UAB, he investigated several aspects of post-transplant complications, including erythrocytosis and recurrent IgAN. Dr. Julian’s IgAN publications include 157 papers and 15 book chapters based on studies to unravel of pathogenesis of the disease. In 1986, he was one of the four founders of the IgA Nephropathy Club, the forerunner of the International IgA Nephropathy Network. Since retirement from clinical activities at UAB in 2022, he continues to work at Reliant Glycosciences LLC, a start-up biotech company for which he was one of five UAB faculty co-founders. The company’s goal is to develop non-invasive biomarkers for IgAN.
Yuko Makita
MODERATED E-POSTER SESSION
Moderator
DAY 2: Friday 19 September 2025, 16:00–17:00
• M.D., Juntendo University, Tokyo, Japan (2008)
• Ph.D. in Medicine, Juntendo University Graduate School (2017)
• Clinical training in internal medicine and nephrology at Juntendo University Hospital (2008–2013)
• Assistant Professor, Department of Nephrology, Juntendo University Hospital (2017–2022)
• Currently Research Fellow, Nephrology, Toronto General Hospital (since 2022)
Renato Monteiro
PLENARY SESSION 4: IgAN Pathogenesis 2
Chair
DAY 2: Friday 19 September 2025, 10:00–11:00
Renato Monteiro is a nephrologist, professor of immunology at Paris Cité University and former head of the Center for Research on Inflammation – INSERM & CNRS - located at Bichat Hospital campus of Paris Cité University in the north of Paris, France. After obtaining his medical degree in Brazil and then completing a residency in nephrology, he moved to Paris in 1982 to study immunonephrology at the Necker Hospital under the mentoring of Prof. Jean Berger. Prof. Monteiro was awarded the 1986 Prize of the French Society of Nephrology for his work on IgA nephropathy (IgAN), notably for the identification of abnormal mesangial IgA in Berger’s disease. He later studied immunology at the University of Birmingham in Alabama with Prof. Max Cooper. Prof. Monteiro’s work in Prof. Cooper’s lab led to the identification of the IgA Fc receptor I (CD89). Professor Monteiro has made important discoveries in the field of IgA and Fc receptors. Prof. Monteiro awarded the 2010 Prize of the French Society of Immunology for his work on CD89. His research group also identified CD71 transferrin receptor as an mesangial and enterocyte IgA1 receptor. His team did pioneered studies in involvement of CD89 and CD71 in diseases involving the IgA system such as IgAN, Henoch-Schönlein purpura, alcoholic cirrhosis, and celiac disease. His group developed a humanized mouse model of IgAN expressing human IgA1 and CD89. Recently, his team demonstrated the role of microbiota in galactose deficient IgA1-induced autoimmunity in IgAN patients and in mouse models.
Jan Novak
PLENARY SESSION 3: IgAN Pathogenesis 1
Chair
DAY 1: Thursday 18 September 2025, 14:00–15:00
Jan Novak is a Distinguished Professor in the Department of Microbiology at the University of Alabama at Birmingham (UAB), Birmingham, AL, USA. He received BS and MS in Biology from the Charles University, Prague, Czech Republic and PhD in Cell and Molecular Biology from the Czech Academy of Sciences. He has been at UAB since 1992.
His research interests include glycoimmunobiology and functional glycomics in health and disease, informing the emerging field of Glycomedicine. Major topics include renal and autoimmune diseases, infectious diseases, and biologically active compounds. Dr. Novak has been involved in many collaborative interdisciplinary studies, including those related to IgA nephropathy. These studies provided basis for the multi-hit hypothesis for the pathogenesis of IgA nephropathy that informs development of disease-specific treatments and biomarkers.
Jenny Nystrom
PLENARY SESSION 3: IgAN Pathogenesis 1
Chair
DAY 1: Thursday 18 September 2025, 14:00–15:00
Jenny Nystrom, PhD, is Professor of Renal Physiology and Dean of the Medical faculty at University of Gothenburg. She is the Head of The Lundberg Laboratory for Kidney Research and a PI with a research group mainly focusing on glomerular cell cross talk and IgA nephropathy. The projects are focused on understanding the role of the mesangial cells in the glomerulus, especially in the onset and progression of IgAN. Her group has shown by transcriptomic profiling that mesangial cells are key players in the signaling events triggered by the pathologic processes leading to IgAN. Her research group is also part of a multi-omics approach for better understanding of renal function in disease. In addition, she has been a part in exploring new treatment options for renal clear cell carcinoma which is currently in clinical trial. She has also a keen interest in educating students and fellows in the area of renal physiology.
Vlado Perkovic
Perspectives in IgAN: Where are we and where do we need to go next?
Speaker
DAY 3: Saturday 20 September 2025, 09:00–10:00
Scientia Professor Vlado Perkovic is the Provost at UNSW Sydney, and previously the Dean of the Faculty of Medicine and Health at UNSW, a Professorial Fellow at The George Institute, Australia, and was a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is clinical trials, and he is a globally recognised expert in kidney trials, trial methodology and operations. He previously established the CRO George Clinical as a subsidiary of the George Institute (now sold), was Executive Director of that organisation for several years, and continues to serve on the Board. He has led several major international clinical trials that have changed treatment paradigms, including trials that have underpinned the approval of 3 new drugs, all of which were first in class in kidney disease. He currently leads the Steering Committees of several ongoing trials and has recently established the first global patient registry and platform trial in chronic kidney disease. He has been involved in developing Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management.
He was previously foundation Chair of the International Society of Nephrology Advancing Clinical Trials (ISN ACT) initiative, the Chair of the Scientific Committee of the Australasian Kidney Trials network, President of the Australian Association of Medical Research Institutes, and a Board Director for the Australian Clinical Trial Alliance. He continues to serve on the Boards of several Medical Research Institutes, as well as George Clinical and St. Vincents Health Australia
Vlado holds a Doctor of Philosophy from the University of Melbourne and completed his undergraduate training at The Royal Melbourne Hospital. He is a Fellow of the Royal Australasian College of Physicians, of the Australian Academy of Health and Medical Sciences and of the American Society of Nephrology.
Evangeline Pillebout
PLENARY SESSION 7: IgAN & IgAV in children
Chair
DAY 3: Saturday 20 September 2025, 10:00–11:00
Dr. Evangeline Pillebout, Ph.D. is a Nephrologist at the St Louis Hospital in Paris, specializing in the areas of nephrology, hypertension, renal transplantation, and clinical research. Her educational background includes a Ph.D. in nephrology, multiple diplomas and certifications in areas of autoimmune diseases, nephrology, and experimental animal research. She completed her nephrology internship and residency at the Public Hospitals of Paris (AP-HP) and has been a full-time attending physician at Saint Louis Hospital since 2006.
Her primary research interests lie in the pathophysiology and clinical management of IgA vasculitis (IgAV) and IgA nephropathy (IgAN), with a focus on improving outcomes for patients. She has been the principal investigator for several landmark studies, including CESAR, HSPronostic, PIC-R, and COLCHIVAS. Her work has helped to advance our understanding of IgA-related kidney diseases and other renal pathologies, and she has made significant contributions to the development of novel therapeutic strategies.
An active contributor to the scientific community, Dr. Pillebout has published extensively in leading journals on topics such as IgA vasculitis, kidney transplantation, and nephrology. Her work is widely cited in both academic and clinical circles. She is also a member of the International IgAN Network Research Group and the European IgAV Study Group, furthering international collaboration and research in the field of nephrology.
Dr. Pillebout has presented her research at numerous conferences and seminars worldwide, sharing her expertise on IgA vasculitis, nephropathy, and advancements in kidney disease treatments. Her ability to translate cutting-edge research into clinical practice has earned her recognition as a leading expert in nephrology.
Ian Roberts
PLENARY SESSION 8: IIGANN Research Group Lecture 3
Chair
DAY 3: Saturday 20 September 2025, 11:30–11:50
Ian Roberts is Professor of Cellular Pathology at the University of Oxford, UK, and Director of Renal Pathology for Oxford University Hospitals. His research interests include IgA nephropathy and classification of glomerular diseases. He is a lead author of the Oxford Classification of IgA nephropathy, review pathologist for VALIGA and follow-up studies, and lead pathologist for a number of international IgA nephropathy studies. He has had leading roles in several international organisations, including International Academy of Pathology (President of BDIAP), Renal Pathology Society (President), International Society of Nephrology (Chair of Pathology Working Group) and European Society of Pathology (Chair of Nephropathology Working Group).
Brad Rovin
PLENARY SESSION 9: Treatment 2
Chair
DAY 3: Saturday 20 September 2025, 14:00–15:00
Dr. Brad H. Rovin is the Lee A. Hebert Professor of Nephrology. Dr. Rovin received his Bachelor of Science in Chemical Engineering from Northwestern University in Evanston Illinois and his Doctor of Medicine from the University of Illinois Medical School in Chicago, Illinois. He completed a residency in Internal Medicine at Barnes Hospital in St. Louis Missouri, and a Fellowship in Nephrology at Washington University School of Medicine, St. Louis. He joined the Ohio State University College of Medicine Faculty in 1990, became Director of the Division of Nephrology in 2004, and served as Vice Chairman of Medicine for Research from 2009-2019. In 2019 he became the Medical Director of the Ohio State University Center for Clinical Research Management.
Dr. Rovin has had several committee and leadership roles in the American Society of Nephrology, including the annual meeting program committee, running the Glomerular Diseases Pre-Course and Co-Editing NephSAP-Glomerular Diseases, a continuing education program of the Society. He serves as deputy Editor of Kidney International, the flagship journal of the International Society of Nephrology, and he is Co-Chair for glomerular disease guideline development for the Kidney Disease Improving Global Outcomes effort. Most recently he received the Evelyn Hess Award from the Lupus Foundation of America for research contributions to improve the understanding of lupus nephritis.
Dr. Rovin’s laboratory studies the immunopathogenesis of glomerular and autoimmune diseases and focuses on biomarker development for non-invasive assessment of kidney pathology. He is heavily involved in clinical trial development and design for investigator-initiated and industry-sponsored trials. He is a founding member of NephroNet, a grass-roots nephrology clinical trial organization, and the Lupus Nephritis Clinical Trials Network. He is and has been the Principal Investigator on several trials of novel therapeutics for glomerular diseases.
Julio Saez-Rodriguez
PLENARY SESSION 8: IIGANN Research Group Lecture 3
The IgAN Atlas
DAY 3: Saturday 20 September 2025, 11:30–11:50
Julio Saez-Rodriguez is Head of Research at the European Bioinformatics Institute (EMBL-EBI), Cambridge, UK, Professor on leave of Medical Bioinformatics and Data Analysis at the Faculty of Medicine of Heidelberg University, a member of the Heidelberg ELLIS Unit, and a co-director of the DREAM challenges. He holds a PhD in Chemical Engineering. He was a postdoctoral fellow at Harvard Medical School and M.I.T., group leader at EMBL-EBI, and professor at RWTH Aachen.
He is interested in developing and applying computational methods to acquire from omics data a functional understanding of biological networks and their deregulation in disease, and to apply this knowledge to develop novel therapeutics. Current emphasis in his group is on use of single-cell technologies, multi-omics integration, and understanding multi-cellular communication. Application areas include cancer, autoimmune, and cardiovascular diseases. More information at www.saezlab.org.
Bonnie Schneider
PANEL DISCUSSION: How do we ensure treatments are available to everyone with IgAN?
Panellist
DAY 2: Friday 19 September 2025, 09:00–10:00
In 2004, Bonnie’s son Eddie was diagnosed with IgA Nephropathy. After finding a lack of information available and hearing that there was no ongoing research to find a cure, she quit her job in marketing and started the IgA Nephropathy Foundation with her husband, Ed. Bonnie works full time as Director of the Foundation.
John Sim
PLENARY SESSION 1: IgAN Natural History
North America
DAY 1: Thursday 18 September 2025, 10:00–11:00
I am a nephrologist and clinical researcher at Kaiser Permanente Southern California (KPSC). I am also the KPSC lead for chronic kidney disease (CKD) Quality and Analysis. I am also the Director for Graduate Medical Education, Simulation Center, and Research for the Los Angeles Medical Center. I also serve as the director of the first Kaiser Permanente Internal Medicine Residency Research Track. For nearly 20 years, my research has focused on hypertension, glomerular diseases, polycystic kidney disease, cardiovascular outcomes, CKD related risk factors and progression, and the epidemiological aspects of these fields. I was one of the co-investigators on the United States Renal Data Systems special subcenter study on Transitions of Care in CKD focusing on knowledge gaps and optimal strategies for management of CKD patients during the critical period where they transition to end-stage kidney disease (ESKD). Currently, I am co-investigator of the NIH funded RELATE-CKD study evaluating real world blood pressure management strategies for CKD patients. At KPSC, I have headed several projects in glomerular disease leveraging one of the largest glomerular disease databases in the United States utilizing our pathology and electronic health records.
Dr. John J. Sim is a nephrologist and clinical researcher at Kaiser Permanente Southern California (KPSC). He is also the KPSC lead for chronic kidney disease (CKD) Quality and Analysis. He is also the Director for Graduate Medical Education, Simulation Center, and Research for the Los Angeles Medical Center. He also serves as the director of the first Kaiser Permanente Internal Medicine Residency Research Track. For nearly 20 years, his research has focused on hypertension, glomerular diseases, polycystic kidney disease, cardiovascular outcomes, CKD related risk factors and progression, and the epidemiological aspects of these fields. He was one of the co-investigators on the United States Renal Data Systems special subcenter study on Transitions of Care in CKD focusing on knowledge gaps and optimal strategies for management of CKD patients during the critical period where they transition to end-stage kidney disease (ESKD). Currently, he is co-investigator of the NIH funded RELATE-CKD study evaluating real world blood pressure management strategies for CKD patients. At KPSC, he has headed several projects in glomerular disease leveraging one of the largest glomerular disease databases in the United States utilizing our pathology and electronic health records.
Sydney C.W. Tang
PLENARY SESSION 6: Treatment 1
How best to manage CKD in IgAN?
DAY 2: Friday 19 September 2025, 14:00–15:00
Sydney Tang is currently Chair of Renal Medicine and Yu Professor in Nephrology at The University of Hong Kong. He graduated from HKU with MBBS and subsequently MD and PhD degrees. He trained in Nephrology at Queen Mary Hospital (Hong Kong) and in basic sciences at King’s College London (UK) and the University of Washington (USA). His research interests include the pathogenetic mechanisms of diabetic and proteinuric kidney disease, and the treatment of IgA nephropathy. He has published over 330 SCI articles and written over 30 book chapters including one on diabetic kidney disease in Comprehensive Clinical Nephrology. He is an Associate Editor of the Journal of the American Society of Nephrology (JASN), Editorial Board member of Kidney International (KI), CJASN, American Journal of Nephrology and Kidney Diseases, and the previous Editor-in-Chief of Nephrology (Carlton). He is the President of the Asian Pacific Society of Nephrology, Chair of the CME Program Committee of the ISN and a previous Executive Committee Member of KDIGO. Locally, he serves the Hong Kong College of Physicians as Council Member and Chairman of the Specialty Board in Nephrology and is a past chairman of the Hong Kong Society of Nephrology.
Hernán Trimarchi
PANEL DISCUSSION: How do we ensure treatments are available to everyone with IgAN?
Chair
DAY 2: Friday 19 September 2025, 09:00–10:00
Professor Hernán Trimarchi was born in Buenos Aires, Argentina in 1967. He graduated from the University of Buenos Aires Medical School in Argentina in 1990. In nephrology, his particular interest is focused on glomerular diseases, particularly in proteinuria and podocyturia, glomerular diseases with main interest in IgA nephropathy, focal and segmental glomerulosclerosis and Fabry disease, in the endothelium in renal replacement therapies, among other topics. His research developed first at Baylor School of Medicine, Houston, Texas, USA where we completed a post-doctoral renal research fellowship in 1997-1998, and continues nowadays at the Hospital Británico de Buenos Aires, Argentina. He has been appointed as head of the Division of Nephrology and Renal Transplantation at the Hospital Británico de Buenos Aires since 2006.
Professor Trimarchi is a former council member of the Glomerular Diseases Committee of the Buenos Aires Nephrology Association and of the Argentine Society of Nephrology. He has been member of many Scientific Committees of the Argentine Congress of Nephrology for the past 15 years. He is a member of the Steering Committee of the International IgA Nephropathy Network, member of the ISN Continuing Medical Education (CME) Program Committee since 2020, ISN member of the ISN Latin America Regional Board since 2021, and Editor-in-Chief of the Journal of the Argentinian Society of Nephrology “Nefrología Argentina”. He is a Fellow of the American Society of Nephrology (FASN), of the American College of Physicians (FACP) and of the International Society of Nephrology (FISN). He is an active member of the International Society of Nephrology and of the International Society of Transplantation (IST). His PhD degree in 2010 was about the endothelium in chronic hemodialysis. He has been awarded the Miatello Prize of the Argentine Society of Nephrology in 2003, 2013 and 2015 and the Lanari Prize of the Argentine Society of Nephrology in 2016; he also won the yearly Hospital Británico de Buenos Aires Clinical Research Award consecutively from 2007 to 2012. He was awarded the Facultad de Medicina at the Universidad de Buenos Aires Prize in 2013 for his research in endothelium and homocysteine in chronic kidney disease. He is member of the editorial board of many nephrology and transplantation journals and has written many book chapters on endothelium, hypertension, glomerulonephritis and transplantation. He is the main editor of the book Glomerular Diseases in 2017, the first of its kind in Spanish. He is also involved in many clinical research protocols related to glomerular diseases, in which he participates as member of the advisory board, steering committees as key opinion leader, or national coordinator of many of them. Finally, Dr Trimarchi is Professor of Medicine of the Universidad Católica Argentina and Director of the Post Graduate Course of Internal Medicine of the Universidad de Buenos Aires School of Medicine at the Hospital Británico
His scientific work encompasses more than 15 chapters in books, 130 original papers, reviews and editorials in peer-reviewed journals, of which over 100 are indexed in PubMed.
Finally, he has been the PI in over 15 sponsored clinical trials related to hypertension, IgA nephropathy, membranous nephropathy, lupus nephritis, focal and segmental glomerulosclerosis and chronic kidney disease.
Marina Vivarelli
PLENARY SESSION 7: IgAN & IgAV in children
Beyond the IPNA Guidelines-Treatment of IgAN & IgAV
DAY 3: Saturday 20 September 2025, 10:00–11:00
Dr Marina Vivarelli trained in Pediatrics at the University of Pavia, Italy. She completed a Research Fellowship at Harvard University - Children’s Hospital Boston with Prof Raif Geha, studying murine B cell function.
Since 2023, she heads the Laboratory of Nephrology and the Clinical Trial Center of the Bambino Gesù Children’s Hospital.
She co-chairs the European Rare Kidney disease Network (ERKNet) Working Group on TMAs and its Registry, is a Fellow of the European Society of Pediatric Nephrology and on the Scientific Advisory Board of ERA. She is also a member of the Editorial Board of Kidney International and JASN. She has co-chaired International Pediatric Nephrology Association guidelines for CNS, SRNS, SSNS and IgAN/V, the KDIGO Guidelines of glomerular diseases and co-chaired National Kidney Foundation and KDIGO projects on complement-mediated renal diseases.
Muh Geot Wong
PLENARY SESSION 8: IIGANN Research Group Lecture 3
Chair
DAY 3: Saturday 20 September 2025, 11:30–11:50
Dr Wong is an Associate Professor in Medicine, University of Sydney, Senior Consultant Nephrologist and Director of Renal Research at the Concord Repatriate General Hospital, Sydney, He is a Clinician researcher with a strong interest in understanding the pathomechanism of kidney fibrosis and has actively promoted the development of both clinical and pre-clinical research in delaying chronic kidney disease (CKD) progression in glomerular diseases, including IgA nephropathy, FSGS, diabetic nephropathy, and management of cardiovascular complications associated with CKD. He is a steering committee member of the Sydney Local Health District (SLHD) Clinical Trial group that will develop a coordinated and system-wide approach to clinical trials management within the SLHD and provide strategic direction for future initiatives. He co-Chair the local organising committee for the Annual Scientific Meeting, Australia New Zealand Society of Nephrology, Sydney 2022, and is the current Chair of the Education Committee for the Asia Pacific Society of Nephrology (ANZSN). He has served as Chair of the Oceania South East Asia Regional Board, International Society of Nephrology, and is an Honorary Executive Officer for the ANZSN.
Xueqing Yu
PLENARY SESSION 4: IgAN Pathogenesis 2
Chair
DAY 2: Friday 19 September 2025, 10:00–11:00
Prof. Yu Xueqing currently serves as the president of Guangdong Provincial People’s Hospital/Guangdong Academy of Medical Sciences. He holds academic positions including President of Asian-Pacific Society of Nephrology, former president of International Society for Peritoneal Dialysis, former Executive Committee member of the International Society of Nephrology, President of Asian Renal Association, Editor-in-Chief of Kidney Diseases, Editor board member of American Journal Kidney Diseases and Kidney International, subject editor of Nephrology.
He undertakes 60 scientific research funds. He is the winner of 9 prizes including 1 second prize National Sci-Tech Advance Award, 1 Sci-Tech Progress Award of the Ministry of Education, and 1 first prize of the Natural Science of Guangdong province. He has authored more than 500 scientific papers, among which 200 were indexed by SCI, including Nature Genetics, Nature Communications, Cell Metabolism, Science Translational Medicine, etc. He has published 17 academic monographs, including 8 chief editors. Prof. Yu is also Changjiang Scholarship professor of Ministry of Education, winner of National Fund for Distinguished Young Scholars. He established a Peritoneal Dialysis Center with world leading patient survival and technical survival rates, The prestigious academic journal Lancet describes him as “a driving force in Chinese nephrology”.
Xu-jie Zhou
MODERATED E-POSTER SESSION
Moderator
DAY 2: Friday 19 September 2025, 16:00–17:00
Dr. Xu-jie Zhou is an associate professor and principal investigator at Peking University First Hospital. His research focuses on IgA Nephropathy (IgAN), particularly its genetic mechanisms, pathophysiology, and potential treatments. Dr. Zhou has authored over 80 peer-reviewed papers as first or corresponding author. His work appears in prestigious journals including Nature Genetics, Annals of the Rheumatic Diseases, Kidney International, and the Journal of the American Society of Nephrology. Dr. Zhou's contributions have significantly advanced our understanding of IgAN, the most common form of glomerulonephritis. His ongoing research aims to translate scientific discoveries into improved clinical outcomes for patients with kidney disorders.
